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Abstract
Background: Human Papillomavirus (HPV) E2 plays several important roles in the viral cycle, including the
transcriptional regulation of the oncogenes E6 and E7, the regulation of the viral genome replication by its
association with E1 helicase and participates in the viral genome segregation during mitosis by its association with
the cellular protein Brd4. It has been shown that E2 protein can regulate negative or positively the activity of
several cellular promoters, although the precise mechanism of this regulation is uncertain. In this work we
constructed a recombinant adenoviral vector to overexpress HPV16 E2 and evaluated the global pattern of
biological processes regulated by E2 using microarrays expression analysis.
Results: The gene expression profile was strongly modified in cells expressing HPV16 E2, finding 1048 down-
regulated genes, and 581 up-regulated. The main cellular pathway modified was WNT since we found 28 genes
down-regulated and 15 up-regulated. Interestingly, this pathway is a convergence point for regulating the
expression of genes involved in several cellular processes, including apoptosis, proliferation and cell differentiation;
MYCN, JAG1 and MAPK13 genes were selected to validate by RT-qPCR the microarray data as these genes in an
altered level of expression, modify very important cellular processes. Additionally, we found that a large number of
genes from pathways such as PDGF, angiogenesis and cytokines and chemokines mediated inflammation, were
also modified in their expression.
Conclusions: Our results demonstrate that HPV16 E2 has regulatory effects on cellular gene expression in HPV
negative cells, independent of the other HPV proteins, and the gene profile observed indicates that these effects
could be mediated by interactions with cellular proteins. The cellular processes affected suggest that E2 expression
leads to the cells in to a convenient environment for a replicative cycle of the virus.
Background
Human Papillomavirus (HPV) is a small DNA virus that
infects squamous epithelia performing a life cycle closely
related to the differentiation program of the target cells
[1]. HPV of the high-risk group (HR) as types 16 and
18, are associated with cervical cancer (CC) develop-
ment while the low risk group as types 6 and 11, only
with benign lesions. The HPV-HR E6 and E7 gene pro-
ducts are oncoproteins, since E6 binds to p53 inducing
its degradation and blocking its function as tumor
suppressor, while E7 binds proteins members of the
“pocket” family as Rb, blocking its union to the tran-
scription factor E2F and inducing the transcription of
genes necessary for the transition towards S phase of
the cell cycle [2]. The E6 and E7 gene expression is
regulated in early stages of the viral infection by the E2
virus protein. This protein also plays several important
roles in the viral cycle, since it regulates the replication
of the viral genome together with E1 protein [3] and
participates in the viral genome segregation through the
cellular mitosis by its association with the cellular pro-
tein Brd4 [4]. During CC progression, the HPV genome
is frequently integrated into cellular chromosomes loos-
ing the expression of E2 and driving to an uncontrolled
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cellular transformation [5-7]. Evidences indicate that E2
protein can regulate negative or positively the activity of
several promoters of cellular genes, although the precise
mechanism of this regulation is not yet well understood.
For example, HPV-HR E2 protein negatively regulates
the expression of b4-integrin gene [8], as well as the
activity of the promoter of hTERT [9]. On the other
hand, E2 has a positive regulation on the expression of
several cellular genes including p21 [10], involucrin [11],
and SF2/ASF [12] with an incomplete knowledge of the
mechanism; however, it is believed that also involves its
interaction with cellular proteins such as Sp1 [10], the
transcription factor C/EBP [11], or TBP and compo-
nents of the basal transcription machinery [12].
It has been demonstrated that the expression of E2
affects important cellular processes as cellular prolifera-
tion or death [13-15]. These effects are mainly mediated
by its interaction with p53 [16,17] and possibly with
TBP-associated factor 1 (TAF1), which regulates the
expression of several genes that modulate cell cycle and
apoptosis [18]. These interactions could induce changes
in the expression of genes involved in these processes.
All the above mentioned reports have focused on ana-
lyzing the effects of E2 on particular promoters and very
specific biological processes; therefore in this study our
aim was to identify in a comprehensive way cellular
genes and biological processes regulated by HPV16 E2.
Using an adenoviral vector we expressed the HPV16 E2
gene in C-33A cells and analyzed the cellular gene
expression profile generated by microarrays hybridiza-
tion; ontological analysis indicated several pathways and
cellular processes altered by HPV16 E2 expression.
Methods
Cell lines and culture conditions
The HEK293 and C-33A cell lines were obtained from
ATCC. HEK293 cells were cultured in Dulbecco’s modi-
fied Eagle’s medium (DMEM), supplemented with 10%
fetal bovine serum (FBS), penicillin (100 units/ml) and
streptomycin (100 μg/ml). The C-33A cell line was cul-
tured in Dulbecco’s modified Eagle’s medium: Nutrient
Mixture F12 (DMEM-F12) supplemented with 10%
Newborn Bovine Serum. Both cell lines were maintained
in an humidified atmosphere at 37°C and 5% CO2.
Recombinant Adenovirus and Infection
The construction of the replication deficient recombi-
nant Adenovirus containing the E2 gene from HPV16
controlled by the cytomegalovirus promoter (CMV) was
carried out with the Adeno-X Expression System (Clon-
tech, Inc). The gene E2 was amplified by PCR using the
primer forward 5’-TTCGGGATCCATGGAGACTCTT
TGCCAACG-3’ and the primer reverse 5’-ATCCGAA
TTCTCATATAGACATAAATCCAGTAG-3’ using as a
template the plasmid pcDNA3-E2. The corresponding
amplicon was cloned in the pShuttle plasmid (Clontech,
Inc) using the EcoRI and KpnI restriction sites. The
generated pShuttle-E2 was digested with the restriction
enzymes PI-SceI and I-CeuI to obtain the expression
unit, and then clone it in the correspondent restriction
sites of the pAdenoX plasmid (Clontech, Inc) generating
the vector pAdenoX-E2. A pAdenoX-empty vector was
also built, incorporating the PI-SceI-I-CeuI fragment
from the pShuttle plasmid. This vector allowed us to
generate an Adenovirus that does not contain expres-
sion cassette, denominated empty Adeno (Ad-empty).
The recombinant viruses were generated by transfection
into HEK293 cells with Lipofectamine Transfection
Reagent (Invitrogen). The viral particles were propa-
gated in HEK293 cells and purified using the system
Adeno-X Mini Purification Kit (Clontech, Inc), following
the instructions of the provider. The Adenovirus titer
was obtained by immunocytochemistry following the
protocol reported by Bewig [19]. For the infection of C-
33A with the recombinant Adenoviruses, 800,000 cells
were seeded in DMEM-F12 with 10% Newborn Bovine
Serum and maintained at 37°C and 5% of CO2 during
24 hrs. The cell cultures were then incubated with 500
moi (multiplicity of infection) of either AdE2 HPV16 or
Ad-Empty during 1.5 hrs in serum free DMEM-F12, in
order to allow the virus adsorption. The viral stock was
then removed away and the infection continued during
48 hrs in DMEM-F12 with 1.5% newborn bovine serum.
To evaluate the infection efficiency, viral DNA was
extracted using the Hirt method [20] and this material
used as a template to amplify by PCR a 287 bp fragment
of the Adenovirus 5 genome, using as a primer forward:
5’-TAAGCGACGGATGTGGCAAAAGTGA-3’ and as a
reverse 5’-CGTTATAGTTACGATGCTAGAGATT-3’.
RT - PCR
Total RNA from the recombinant Adenovirus infected
cells was obtained using the Trizol reagent (Invitrogen)
following the indications of the provider. One μgo f
RNA was used to synthesize cDNA using M-MLV
reverse transcriptase (Promega). This cDNA was used as
a template to perform a PCR reaction using as primer
forward 5’-TTCGGGATCCATGGAGACTCTTTGC-
CAACG-3’ and as reverse 5’-ATCCGAATTCTCATA-
TAGACATAAATCCAGTAG-3’ amplifying a 1098 bp
fragment corresponding to the full length HPV16 E2
gene. We used also a primer forward 5’-CTGTGGA
CCGTGAGGATA-3 and a reverse 5’-CTGTTGGGCA-
TAGATTGTT-3’ t oa m p l i f yb yP C Ra7 5 0b pf r a g m e n t
of the Ad-5 Hexon gene.
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Page 2 of 10Hybridization and analysis of microarrays data
10 μg of total RNA were used for cDNA synthesis and
labeling with SuperScript II kit (Invitrogen), using in a
first array dUTP-Cy3 incorporation for Non-infected
cells (N.I.) and dUTP-Cy5 for Ad-empty; and in a sec-
ond array dUTP-Cy3 for Ad-empty and dUTP-Cy5 for
AdE2; Fluorophorus incorporation efficiency was ana-
lyzed measuring absorbance at 555 nm for Cy3 and 655
nm for Cy5. Similar quantities of fluorophorus labeled
cDNA were hybridized on the oligonucleotides collec-
tion 50-mer Human10K from MWGBiotech Oligo Bio
Sets (Germany). Images of the microarrays were
acquired and quantified in the scanner ScanArray 4000
using the QuantArray software from Packard BioChips
(USA). A first analysis of the images and their data were
performed using the Array-Pro Analyzer software from
Media Cybernetics (USA). Data were then normalized
and analyzed with genArise software (Institute of Cellu-
lar Physiology, UNAM) and genes with a Z score ≥ 1.8
or ≤ -1.8 were considered with altered expression. An
ontological analysis was performed with selected data
using PANTHER classification system (Protein ANalysis
THrough Evolutionary Relationships).
Quantitative Reverse Transcription PCR (RT-qPCR)
Total RNA from recombinant Adenovirus infected cells
was obtained using Trizol reagent (Invitrogen) following
the indications of the provider; 1 μgo fR N Aw a su s e d
to synthesize cDNA with M-MLV reverse transcriptase
(Promega) and this material used for relative quantifica-
tion of the selected genes obtained from the microarrays
analyses, by qPCR using the commercial kit ABSOLUTE
qPCR SYBR Green Mix (Abgene) following the recom-
mendations of the provider. The evaluation of the
mRNA levels of the gene of constitutive expression
GAPDH was used to normalize. Amplicons quantifica-
tion was performed by double delta Ct (ΔΔCt) method.
The primer sequences used were: for GAPDH as for-
ward 5’-CATCTCTGCCCCCTCTGCTGA-3’ and as
reverse 5’-GGATGACCTTGCCCACAGCCT-3’;f o rN -
MYC as forward 5’-TACCTCCGGAGAGGACACC-3’
and as reverse 5’-CTTGGTGTTGGAGGAGGAAC-3’;
for JAG1 as forward 5’-CTTCAACCTCAAGGCCAGC-
3’ and as reverse 5’-CTGTCAGGTTGAACGGTGTC-3’;
and for MAPK13 as forward 5’-ATGTCTTCACCC-
CAGCCTC-3’ and as reverse 5’TCCTCACTGAAC
TCCATCCC3’.
Results
E2 expression in AdE2 infected C-33A cells
In order to obtain reliable data on the modifications
induced by HPV16 E2 on the cellular gene expression
profile, a recombinant adenoviral vector was used, since
these vectors are able to efficiently infect cells from
epithelial origin and the presence of a very strong
promoter (MLP from HCMV) on its expression unit,
guarantees a high efficiency of transgene expression.
The infection of C-33A cells with the recombinant Ade-
novirus AdE2 was observed in almost 90% of the treated
cell population (not shown). The evaluation of the E2
expression level in cells was carried out by RT-PCR 48
hours after infection, observing a very high amount of
E2 mRNA in the infected cells (Figure 1).
Differences in the transcriptional profiles
In order to identify the modifications induced on the
cellular gene expression profile by HPV16 E2 gene, the
expression profiles of AdE2 C-33A infected cells versus
the expression profile of Ad-empty infected cells were
obtained. To discriminate the effect that the adenoviral
vector by itself had on the cellular gene expression, we
also compared the expression profile of Ad-empty
infected cells against that one from non-infected cells
(mock). Data analysis obtained indicates that HPV16 E2
up-regulates 581 genes and down-regulates 1048 genes
(Additional file 1, Table S1 and Additional file 2, Table
S2). Table 1 shows a list of the 50 genes with higher
induction (with a Z score >2.1) and Table 2 those 50
g e n e sh i g h l yd o w n - r e g u l a t e d( w i t haZs c o r e< 2 . 9 )f o r
the expression of E2. These results indicate that HPV16
E2 has preferably a negative effect on cellular gene
expression.
Figure 1 Expression of E2 in AdE2 infected C-33A cells. C-33A
cells were infected with 500 moi of AdE2 or Ad-empty; 48 hours
post-infection RNA was extracted from both cultures and also from
non-infected cells (N.I.), cDNA was synthesized and PCR performed
to detect the HPV16 E2 ORF. E2 was efficiently expressed in AdE2
infected C-33A cells; a comparison with GAPDH expression indicates
the high E2 expression in those cells.
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Gene ID Symbol Name Fold Change
NM_017839 LPCAT2 Lysophosphatidylcholine acyltransferase 2 5.3
NM_002071 GNAL Guanine nucleotide binding protein (G protein) 4.9
NM_018667 SMPD3 Sphingomyelin phosphodiesterase 3 4.7
NM_004283 RAB3D RAB3D, member RAS oncogene family 4.5
NM_006327 TIMM23 Translocase of inner mitochondrial membrane 23 homolog (yeast) 4.5
NM_017902 HIF1AN Hypoxia inducible factor 1 4.2
NM_001421 ELF4 E74-like factor 4 3.9
NM_023919 TAS2R7 Taste receptor, type 2, member 7 3.9
NM_004289 NFE2L3 Nuclear factor (erythroid-derived 2)-like 3 3.9
NM_003630 PEX3 Peroxisomal biogenesis factor 3 3.8
NM_025087 CWH43 Cell wall biogenesis 43 C-terminal homolog (S. cerevisiae) 3.8
NM_013417 IARS Isoleucyl-tRNA synthetase 3.8
NM_012338 TSPAN12 Tetraspanin 12 3.7
NM_004131 GZMB Granzyme B (granzyme 2) 3.7
NM_002427 MMP13 Matrix metallopeptidase 13 (collagenase 3) 3.6
NM_017849 TMEM127 Transmembrane protein 127 3.6
NM_003821 RIPK2 Receptor-interacting serine-threonine kinase 2 3.6
NM_003958 RNF8 Ring finger protein 8 3.5
NM_004224 GPR50 G protein-coupled receptor 50 3.5
NM_001244 TNFSF8 Tumor necrosis factor (ligand) superfamily, member 8 3.4
NM_020375 C12orf5 Chromosome 12 open reading frame 5 3.4
NM_004219 PTTG1 Pituitary tumor-transforming 1 3.4
NM_005925 MEP1B Meprin A, beta 3.4
NM_024730 RERGL RERG/RAS-like 3.3
NM_014942 ANKRD6 Ankyrin repeat domain 6 3.3
NM_032946 NXF5 Nuclear RNA export factor 5 3.3
NM_004528 MGST3 Microsomal glutathione S-transferase 3 3.3
NM_012280 FTSJ1 FtsJ homolog 1 (E. coli) 3.3
NM_001372 DNAH9 Dynein, axonemal, heavy chain 9 3.2
NM_013256 ZNF180 Zinc finger protein 180 3.2
NM_003569 STX7 Syntaxin 7 3.2
NM_018370 DRAM1 DNA-damage regulated autophagy modulator 1 3.2
NM_017817 RAB20 RAB20, member RAS oncogene family 3.2
NM_020377 CYSLTR2 Cysteinyl leukotriene receptor 2 3.2
NM_022087 GALNT11 N-acetylgalactosaminyltransferase 11 3.2
NM_004426 PHC1 Polyhomeotic homolog 1 (Drosophila) 3.2
NM_031857 PCDHA9 Protocadherin alpha 9 3.2
NM_019863 F8 Coagulation factor VIII, procoagulant component 3.1
NM_018840 C20orf24 Chromosome 20 open reading frame 24 3.1
NM_006243 PPP2R5A Protein phosphatase 2, regulatory subunit B’, alpha isoform 3.1
NM_017946 FKBP14 FK506 binding protein 14, 22 kDa 3.1
NM_025212 CXXC4 CXXC finger 4 3.1
NM_012214 MGAT4A Mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase, isozyme A 3.1
NM_012087 GTF3C5 General transcription factor IIIC, polypeptide 5, 63 kDa 3.1
NM_017952 PTCD3 Pentatricopeptide repeat domain 3 3.1
NM_005967 NAB2 NGFI-A binding protein 2 (EGR1 binding protein 2) 3.1
NM_016021 UBE2J1 Ubiquitin-conjugating enzyme E2, J1 (UBC6 homolog, yeast) 3.1
NM_014945 ABLIM3 Actin binding LIM protein family, member 3 3.1
NM_001006 RPS3A Ribosomal protein S3A 3.1
NM_012200 B3GAT3 Beta-1,3-glucuronyltransferase 3 (glucuronosyltransferase I) 3.1
Fold Change refers to differences in Z score values compared to expression in non-infected cells, analysis was perform using genArise software. Changes in gene
expression with a cut-off >3.1 was used and the p-value was calculated by Student’s t-test.
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Gene ID Symbol Name Fold Change
NM_001872 CPB2 Carboxypeptidase B2 -8.5
NM_024610 HSPBAP1 HSPB (heat shock 27 kDa) associated protein 1 -8.2
NM_022118 RBM26 RNA binding motif protein 26 -8.2
NM_017819 RG9MTD1 RNA (guanine-9-) methyltransferase domain containing 1 -8.1
NM_005319 HIST1H1C histone cluster 1, H1c -7.9
NM_000859 HMGCR 3-hydroxy-3-methylglutaryl-Coenzyme A reductase -7.9
NM_003829 MPDZ Multiple PDZ domain protein -7.8
NM_017806 LIME1 Lck interacting transmembrane adaptor 1 -7.5
NM_005166 APLP1 Amyloid beta (A4) precursor-like protein 1 -7.5
NM_015985 ANGPT4 Angiopoietin 4 -7.3
NM_016283 TAF9 TAF9 RNA polymerase II, TATA box binding protein (TBP)-associated factor -7.0
NM_000808 GABRA3 Gamma-aminobutyric acid (GABA) A receptor, alpha 3 -7.0
NM_005264 GFRA1 GDNF family receptor alpha 1 -7.0
NM_003420 ZNF35 Zinc finger protein 35 -7.0
NM_016179 TRPC4 Transient receptor potential cation channel, subfamily C, member 4 -6.9
NM_020200 PRTFDC1 Phosphoribosyl transferase domain containing 1 -6.9
NM_014736 KIAA0101 KIAA0101 -6.9
NM_020651 PELI1 Pellino homolog 1 (Drosophila) -6.8
NM_006061 CRISP3 Cysteine-rich secretory protein 3 -6.8
NM_014626 TAAR2 Trace amine associated receptor 2 -6.8
NM_007048 BTN3A1 Butyrophilin, subfamily 3, member A1 -6.7
NM_007213 PRAF2 PRA1 domain family, member 2 -6.7
NM_024838 THNSL1 Threonine synthase-like 1 (S. cerevisiae) -6.7
NM_012198 GCA Grancalcin, EF-hand calcium binding protein -6.6
NM_018938 PCDHB4 Protocadherin beta 4 -6.6
NM_006530 YEATS4 YEATS domain containing 4 -6.4
NM_000500 CYP21A2 Cytochrome P450, family 21, subfamily A, polypeptide 2 -6.4
NM_014547 TMOD3 Tropomodulin 3 (ubiquitous) -6.4
NM_000228 LAMB3 Laminin, beta 3 -6.3
NM_002029 FPR1 Formyl peptide receptor 1 -6.3
NM_016508 CDKL3 Cyclin-dependent kinase-like 3 -6.3
NM_017779 DEPDC1 DEP domain containing 1 -6.3
NM_024612 DHX40 DEAH (Asp-Glu-Ala-His) box polypeptide 40 -6.3
NM_020666 CLK4 CDC-like kinase 4 -6.3
NM_007029 STMN2 Stathmin-like 2 -6.2
NM_012095 AP3M1 Adaptor-related protein complex 3, mu 1 subunit -6.2
NM_018319 TDP1 Tyrosyl-DNA phosphodiesterase 1 -6.2
NM_024665 TBL1XR1 Transducin (beta)-like 1 X-linked receptor 1 -6.2
NM_012123 MTO1 Mitochondrial translation optimization 1 homolog (S. cerevisiae) -6.2
NM_001285 CLCA1 Chloride channel accessory 1 -6.2
NM_025074 FRAS1 Fraser syndrome 1 -6.2
NM_017424 CECR1 Cat eye syndrome chromosome region, candidate 1 -6.1
NM_024756 MMRN2 Multimerin 2 -6.1
NM_002492 NDUFB5 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 5 -6.1
NM_004549 NDUFC2 NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 2 -6.1
NM_018128 TSR1 TSR1, 20S rRNA accumulation, homolog (S. cerevisiae) -6.0
NM_000438 PAX3 Paired box 3 -6.0
NM_018991 STAG3L1 Stromal antigen 3-like 1 -6.0
NM_024576 OGFRL1 Opioid growth factor receptor-like 1 -6.0
NM_004249 RAB28 RAB28, member RAS oncogene family -6.0
Fold Change refers to differences in Z score values compared to expression in non-infected cells, analysis was perform using genArise software. Changes in gene
expression with a cut-off < -6.0 was used and the p-value was calculated by Student’s t-test.
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fication system (Protein ANalysis Through Evolutionary
Relationships) [21] indicates that WNT pathway is the
most severely affected by the expression of E2, since we
found 28 genes down-regulated and 15 up-regulated.
Interestingly, this pathway is a convergence point of
genes involved in the regulation of several cellular pro-
cesses, including apoptosis, cell proliferation and differ-
entiation. We found modifications in the expression of
genes that play an important role in regulating these
processes, like the down-regulation of EGR2 and
CASP9, both involved in apoptosis; the up-regulation of
CCNA and down-regulation of RHOA, both involved in
cell proliferation; and the down-regulation of some of
the type I keratins, markers of epithelial cell differentia-
tion such as keratin 14, 24 and 34. Moreover, we found
that a large number of genes from pathways such as
PDGF, angiogenesis and cytokines and chemokines
mediated inflammation, are also altered for expression
of HPV16 E2 (Tables 3 and 4).
Validation of the microarrays data
The validation of the results obtained with the microar-
rays analysis was performed by Real Time RT-qPCR,
evaluating the mRNA levels of some of the genes nega-
tively regulated by E2: MYCN, JAG1 and MAPK13. This
approach was taking as basis recent results about valida-
tion of microarray experiments [22]. These genes were
selected because they have a key role in some of path-
ways altered by HPV16 E2, such as apoptosis, cell cycle
and keratinocyte differentiation [23-25]. Figure 2 shows
the results of RT-qPCR for the selected genes among
the AdE2 infected C-33A cells and those Ad-empty
infected. The results of RT-qPCR from the selected
genes correlate with the observations obtained with the
microarrays analysis, indicating a very trusty landscape
of the modifications on cellular gene expression induced
by HPV16 E2.
Discussion
In this work we report the modification of the gene
expression profile induced by the expression of HPV16 E2.
We used the C-33A cell line to study the changes in
the expression level of 10,000 human transcripts when
the HPV16 E2 is expressed. In C-33A cells there is not
evidence of HPV infection and they represent a conveni-
ent model to study the effect of E2 on cellular gene
expression, without the involvement of another viral
gene. Traditionally it has been considered that the effects
Table 3 Top 10 up-regulated pathways in C-33A cells
expressing E2
Cellular Pathway No. genes
altered
Wnt signaling pathway 15
Inflammation mediated by chemokine and
cytokine signaling pathway
10
Angiogenesis 8
Integrin signalling pathway 8
Cadherin signaling pathway 8
B cell activation 8
Apoptosis signaling pathway 7
PDGF signaling pathway 7
EGF receptor signaling pathway 7
Oxidative stress Response 6
Cellular Pathways with the greatest number of genes up-regulated by HPV16
E2 were selected as main pathways altered by E2. Ontological analysis was
based on the algorithm used by PANTHER system (Protein ANalysis Through
Evolutionary Relationships).
Table 4 Top 10 down-regulated pathways in C-33A cells
expressing E2
Cellular Pathway No. genes
altered
Wnt signaling pathway 28
PDGF signaling pathway 22
Angiogenesis 20
Inflammation mediated by chemokine and
cytokine signaling pathway
20
Integrin signalling pathway 16
TGF-beta signaling pathway 13
p53 pathway 12
FGF signaling pathway 11
Apoptosis signaling pathway 10
PI3 kinase pathway 10
Cellular Pathways with the greatest number of genes down-regulated by
HPV16 E2 were selected as main pathways altered by E2. Ontological analysis
was based on the algorithm used by PANTHER system (Protein ANalysis
Through Evolutionary Relationships).
Figure 2 Evaluation of mRNA levels of selected genes by
RT-qPCR. RNA from AdE2 and Ad-empty infected C-33A cells was
extracted 48 hours post-infection, cDNA was synthesized, and specific
primers used in a qPCR reaction to amplify fragments of the selected
genes. Relative mRNA levels of MAPK13, JAG1 and MYCN genes are
showed; values are expressed as difference in double delta-Ct
compared with non-infected cells and expression of a housekeeping
gene (GAPDH). Bars represent the mean ± SD (P < 0.05).
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protein E2 is expressed in cervical carcinoma derived cell
lines is due to the repression of the expression of the
viral oncogenes E6 and E7 [2,26-28]; however, in this
work we showed that HPV16 E2 induces changes in the
expression of cellular genes, independently of the regula-
tion of the viral oncoproteins E6 and E7.
The present study showed that HPV16 E2 importantly
alters the expression profile of cellular genes, preferen-
tially in a negative way, although a large number of
genes were up-regulated.
It is well known that E2 protein suppress the activity
of papillomavirus promoters by binding to low-affinity
binding sites, leading to the displacement of cellular
binding factors [8,29-31]. A similar scenario has been
proposed for several cellular promoters, since in cul-
tured primary keratinocytes it has been observed that
HPV8 E2 represses the transcriptional activity of the b4
integrin promoter, due in part to its binding to a speci-
fic E2 binding site on the promoter and leading to dis-
placement of at least one cellular DNA binding factor.
However, growing evidence indicates that protein-pro-
tein interactions could be even more significant for E2-
mediated transcriptional regulation of cellular genes
since has been shown that E2 protein from several
papillomavirus physically and functionally interact with
a variety of cellular regulatory transcription factors,
i n c l u d i n gS p 1 ,C / E B P ,C B P / p 3 0 0a n dp 5 3
[10,11,16,32,33]. The interaction with Sp1 is apparently
one of the most relevant for transcriptional regulation
of cellular genes by E2 since it is involved in the down-
regulation of the hTERT promoter by HPV18 E2, but
also the interaction with this transcription factor plays
an important role in the transcriptional activation of
several cellular promoters, including p21 by HPV18 E2
[10] or SF2/ASF by HPV16 E2 proteins [12].
Even when E2 shows cooperative activation with a
variety of sequence-specific DNA binding factors such
as AP1, USF, TEF-1, NF1/CTF, and C/EBP [11,34-37], a
direct interaction between E2 and these cooperation
partners has only been shown for HPV18 E2 with C/
EBP, in the transactivation of the involucrin promoter
[11], suggesting the transcriptional cooperation may also
occur without a direct binding of these cellular proteins
with E2.
The analysis of our data indicated that HPV16 E2
negatively regulates a higher number of genes (1048
genes) than those positively regulated (581 genes) (Addi-
tional file 1, Table S1 and Additional file 2, Table S2). In
agreement with results previously reported [10,11], we
found that HPV16 E2 up-regulate the expression of
involucrin and cyclin-dependent kinase inhibitor 1A
(p21) genes. However, we observed these genes up-regu-
lated at a level below the established cutoffs for our
analysis, indicating the relevance of the data set
provided by our study for understanding the role of
HPV E2 as a regulator of cellular gene expression.
Although we do not rule out the possibility that sev-
eral genes are regulated by a direct interaction of E2
with specific sequences in the particular promoters, the
global effect observed suggest that it could be the conse-
quence of the interaction of E2 with several cellular
transcription factors such as Sp1 (apparently the most
important). E2 protein could destabilize protein-protein
interactions between Sp1 and co-activators resulting in
the negative regulation of the transactivation function of
Sp1 itself, or E2 bound on the promoter via Sp1 may
promote the recruitment of transcriptional co-activators
such as p300/CBP and pCAF, leading to the transactiva-
tion of cellular promoters [38,39].
On the other hand, some HPV E2 proteins have been
shown to interact with TBP and a number of compo-
nents of the basal transcription machinery [18,40-45],
regulating the recruitment of the pre-initiation complex
and affecting both viral and cellular gene expression.
Previous works in our group have demonstrated that E2
protein interacts and cooperates with TAF1 in the acti-
vation of E2-dependent viral promoters [18,40]. An ana-
lysis of our results indicates that 55 genes regulated by
E2 have a natural regulation for TAF1 (data not shown).
Transregulation of specific cellular promoters could be
also dependent on levels of the E2 protein in cells, since
high levels of HPV16 E2 are known to result in inhibi-
tion of cell growth and promotion of apoptosis probably
because with higher E2 levels, cellular metabolism may
be compromised, leading to a reduced ability of cellular
factors to control expression of several cellular genes.
However, even we observed an abundant expression of
E2, cell viability and different metabolic aspects of the
cells (such as cell death) were not affected in a period of
72 hours post-infection witht h eA d e n o E 2v i r u s( d a t a
not shown).
This allows us to assume that the observed modula-
tion of cellular gene expression by E2 is not the conse-
quence of induced quiescence or apoptosis, thus the
mechanisms of gene expression regulation by E2 only
implicate its transcriptional regulatory properties,
strongly influenced by its interaction with cellular
proteins.
As expected, the results of the microarray analysis
showed that HPV16 E2 affect a variety of cellular path-
ways (Tables 3 and 4), some of them altered in early
stages of cervical cancer development, when E2 is still
expressed before the integration of the viral genome
into cell chromosome.
Interestingly we observed that the expression of a high
number of genes on the WNT-pathway is modified for
the expression of E2. In the last few years it has been
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sion of E6 and E7 viral oncogenes [46-48]. However, our
observations suggest that E2 is also targeting this path-
way probably with different consequences than the
induced by the viral oncogenes, since a tight regulation
and controlled coordination of the WNT signaling cas-
cade is required to maintain the balance between prolif-
eration and differentiation. Recently it has been
proposed that essentially all cellular information - i.e.
from other signaling pathways, nutrient levels, etc. - is
funneled down into a choice of coactivators usage,
either CBP or p300, by their interacting partner beta-
catenin (or catenin-like molecules in the absence of
beta-catenin) to make the critical decision to either
remain quiescent, or once entering cycle to proliferate
without differentiation or to initiate the differentiation
process [49]. Since CBP and p300 are also interactors
for E2, the function of the WNT-pathway could be dee-
ply modified by the low availability of the coactivators
when the viral protein is present.
The control of this pathways in the viral cycle could
have biological consequences as in the case of the regu-
lation of cell proliferation, since the induction of Cyclin
A expression by E2, orchestrated with a negative regula-
tion of RhoA, known inhibitor of the cell proliferation,
would allow the entry into the S phase of cell cycle
[50-52]. Similarly, E2 expression could be also involved
in apoptosis regulation since it negatively regulate genes
involved in this process, such as caspase 9 (CASP9) [53],
whose product is an effector of cell death. In the same
way, EGR2 [54,55] is negatively regulated bringing as a
consequence the inhibition of cytochrome c releasing it
from the mitochondria. Interestingly, several genes
mainly expressed in keratinocytes from the basal layers
of stratified epithelia, such as type I keratins (keratin 14,
24 and 34) [56-58], were down-regulated in cells expres-
sing E2 suggesting that the process of cell differentiation
could be also regulated by this viral product.
Conclusion
In conclusion, our results in this work demonstrate that
HPV16 E2 has a regulatory effect on cellular gene
expression independently of the viral oncoproteins E6
and E7. The analysis data presented in this study
demonstrates that E2 predominantly induces a down-
regulation of gene expression. The gene profile observed
in E2 expressing cells suggests that E2 could induce
these changes by its interactions with ubiquitous cellular
proteins such as Sp1. Several genes involved in pathways
altered in early stages of cervical cancer, such as CASP9
a n dE G R 2i n v o l v e di na p o p t o s i sa n dM Y C - N ,C C N A
and RhoA involved in cell proliferation, were altered by
HPV16 E2 expression. The cellular processes affected
suggest that E2 expression leads to the cells in to a con-
venient environment for a replicative cycle of the virus.
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